Windlas Biotech Limited (WINDLAS) Q2 FY27 Financial Results: PAT ₹25 & Revenue ₹248 Cr

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
MetricValue
Revenue₹248 Cr
Net Profit (PAT)₹25
📢 Key Event
Windlas Biotech reports Q1 FY27 results with record revenue and dividend declaration
🔄 What Changed
Revenue grew 18% YoY to ₹248 crores; Adjusted EBITDA up 26% to ₹34 crores; Adjusted PAT up 37% to ₹25 crores; ₹47 crore buyback completed; ₹13 crore dividend declared
🔮 What's Next
Commercialization of Plant-6 in H1 FY27; focus on strengthening partnerships, expanding offerings, and achieving operational excellence
💡 Investor Takeaway
The company delivered record revenue and profitability while returning capital to shareholders through dividend and buyback, signaling confidence in sustained growth.

Windlas Biotech Limited reported record Q1 FY27 revenue of ₹248 crores, up 18% YoY, driven by strong CDMO growth, while adjusted EBITDA rose 26% to ₹34 crores and adjusted PAT increased 37% to ₹25 crores. The company completed a ₹47 crore share buyback without promoter participation and declared a ₹13 crore dividend (₹6.30 per share) for FY26. CDMO vertical contributed 84% of consolidated revenue, with exports growing 79% YoY to ₹11 crores. Management highlighted strategic focus on capacity expansion, portfolio development, and long-term shareholder value creation amid a stable pharmaceutical market.

📄 View Original Announcement (PDF)

About Windlas Biotech Limited (WINDLAS)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,645.02 Cr P/E: 26.4

View full WINDLAS stock details →

📡 Get AI alerts when WINDLAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track WINDLAS — Free

📊 More WINDLAS filings

See all WINDLAS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when WINDLAS files new disclosures

Track WINDLAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track WINDLAS — Free

Free account · 2 AI queries/day